Jefferson et al. reply

doi:10.1038/s41587-025-02765-y

2025-08-12

PRE

Osmat Azzam Jefferson

DOI：10.1038/s41587-025-02765-y

原文链接

原文求助

摘要

期刊

Nature Biotechnology

IF:

41.7

论文数:

1.2W

被引数:

10.1W

机构

duke law school

学者数:

论文数: 2

被引数: 0

cardozo school of law

学者数:

论文数: 1

被引数: 0

引用论文

Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?

VALUE IN HEALTH

IF6

2024-03-01

PREAI

Williamson, Rhys; Munro, Trent; Ascher, David; Robertson, Avril; Pregelj, Lisette

Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes

NATURE BIOTECHNOLOGY

IF41.7

2022-02-15

PREAI

Walsh, Bryan S.; Darrow, Jonathan J.; Kesselheim, Aaron S.

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act

PLOS MEDICINE

IF9.9

2024-04-25

OAAI

Feldman, Robin

Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation

HEALTH AFFAIRS

IF8.1

2021-08-01

PREAI

Van de Wiele, Victor L.; Kesselheim, Aaron S.; Sarpatwari, Ameet